Cytosorbents (CTSO) Equity Average (2011 - 2026)

Cytosorbents (CTSO) has 15 years of Equity Average data on file, last reported at $4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 68.43% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (down 68.43% YoY), and the FY2025 full-year result was $8.5 million, down 50.82% from the prior year.
• Equity Average for Q1 2026 stood at $4.0 million, down from $7.5 million in the prior quarter.
• Across five years, Equity Average topped out at $59.0 million in Q1 2022 and bottomed at $4.0 million in Q1 2026.
• The 5-year median for Equity Average is $21.1 million (2023), against an average of $24.1 million.
• The widest annual swing landed in 2022, when Equity Average retreated 24.58%; it then tumbled 68.43% in 2026.
• A 5-year view of Equity Average shows it stood at $37.3 million in 2022, then plunged by 43.25% to $21.1 million in 2023, then sank by 42.09% to $12.2 million in 2024, then sank by 39.06% to $7.5 million in 2025, then sank by 45.74% to $4.0 million in 2026.
• The last three Equity Average figures came in at $4.0 million (Q1 2026), $7.5 million (Q4 2025), and $10.3 million (Q3 2025), per Business Quant data.

Peer Comparison